Is Wegovy Worth It for Most People Who Try It?

You've read the headlines. Here's what the numbers behind them mean in practice

You've probably seen the 15% figure — and possibly the suggestion that semaglutide is worth it for almost everyone who tries it. The reality is a bit more layered. The STEP 1 study, published in the New England Journal of Medicine, randomised 1,961 adults with obesity and no diabetes over 68 weeks. The average weight loss on 2.4mg semaglutide was about 15%, versus roughly 2.4% on placebo. That is a clinically meaningful gap. But averages conceal a spread: some participants lost considerably more, and a meaningful minority did not respond well. The medicine works through a single GLP-1 pathway, reducing appetite, slowing gastric emptying and increasing the feeling of fullness after meals. What it does not do is override biology entirely, and stopping treatment, without sustained lifestyle change in place, typically leads to weight returning.

So is semaglutide worth it on the results alone? For many people with weight-related health conditions, the answer appears to be yes. But the honest framing is that Wegovy is a tool that works best alongside a reduced-calorie diet and increased activity, not instead of them. A prescriber is the right person to weigh up whether your specific health picture makes it the right tool for you. Our Wegovy overview covers the full evidence base if you want more context before deciding.

The side effects worth knowing about before you commit

The side effects most commonly reported with Wegovy are gastrointestinal: nausea, loose stools, constipation, indigestion and burping appear most often in the early weeks and after dose increases. For a proportion of people they are significant enough to affect daily life; for most they ease within a fortnight or so. Fatigue, headaches and mild dizziness are also reported, particularly in the first weeks.

There are rarer but more serious signals worth knowing. In January 2026, the MHRA issued a Drug Safety Update flagging acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines. Severe, persistent stomach pain that radiates towards the back is a reason to stop treatment and get medical help promptly. Gallbladder problems and allergic reactions are also listed in the safety profile. Hair thinning is a question our prescribers hear regularly, if that's a concern for you, the hair thinning on Wegovy page sets out what the evidence shows. None of this makes Wegovy unsafe, but knowing the full picture before you start is how you make a genuinely informed decision. You can report any suspected side effect through the MHRA's Yellow Card scheme.

Is Wegovy worth it financially? A plain answer to an awkward question

Cost is the part of the question people often feel embarrassed to raise, and it's also the part that most affects whether semaglutide is realistically worth it. Private treatment costs vary by dose and provider. On the NHS, Wegovy is only available through specialist weight management services under the criteria set out by NICE TA875, which requires use within a multidisciplinary service for a maximum of two years, and waiting lists for those services are often long. Most people asking whether Wegovy is worth it are weighing up the private route.

For a thorough breakdown of what private treatment typically costs and what's usually included (or quietly excluded), the Wegovy cost page lays it out plainly. The short version: a legitimate private prescription includes clinical assessment, prescribing and dispensing, any price that seems to omit those things is a red flag, not a bargain. At nume, one price covers the consultation, the prescription, the treatment and free next-working-day delivery, with 7-day aftercare included. Whether that is worth it financially is genuinely personal and depends on how you weigh the health benefits against monthly outgoings. What a prescriber can do, and what a price comparison table cannot, is help you assess how much benefit you're likely to get and for how long.

Who tends to find Wegovy worth it, and who might not

People who tend to report the clearest benefit are those who combine semaglutide with consistent dietary and activity changes, stick with the dose-escalation schedule to minimise GI side effects, and have realistic expectations about the timeline. Sixteen weeks in, at a lower titration dose, is not the moment to judge whether it's working. The full maintenance dose takes months to reach.

It is less likely to feel worth it for people who find side effects difficult to manage and don't have accessible clinical support, who have unrealistic expectations about speed, or who expect results to persist after stopping without any lifestyle foundation in place. Wegovy is not licensed for use in pregnancy, breastfeeding or for people trying to conceive, and it is not suitable for under-18s. Those with a history of certain GI conditions or medullary thyroid carcinoma will need a careful prescriber conversation. A fuller sense of who the medicine is and isn't for, including guidance on Wegovy weight loss in Letchworth and how the semaglutide evidence maps onto different situations, is worth reading before starting. If you have looked at this enough and want a clinical view specific to you, check your eligibility with our prescribers, the consultation is free.